Cargando…

Catheter ablation for atrial fibrillation in patients with end‐stage heart failure and eligibility for heart transplantation

AIMS: Timely referrals for transplantation and left ventricular assist device (LVAD) play a key role in favourable outcomes in patients with advanced heart failure (HF). The purpose of the Catheter Ablation for atrial fibrillation in patientS with end‐sTage heart faiLure and Eligibility for Heart Tr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sohns, Christian, Marrouche, Nassir F., Costard‐Jäckle, Angelika, Sossalla, Samuel, Bergau, Leonard, Schramm, Rene, Fuchs, Uwe, Omran, Hazem, Rubarth, Kerstin, Dumitrescu, Daniel, Konietschke, Frank, Rudolph, Volker, Gummert, Jan, Sommer, Philipp, Fox, Henrik
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Study Designs
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8006697/ https://www.ncbi.nlm.nih.gov/pubmed/33314690 http://dx.doi.org/10.1002/ehf2.13150

Ejemplares similares

Non-invasive assessment of central venous pressure in heart failure: a systematic prospective comparison of echocardiography and Swan-Ganz catheter
por: Szymczyk, Tobias, et al.
Publicado: (2020)

Donor–recipient risk assessment tools in heart transplant recipients: the Bad Oeynhausen experience
por: Schramm, Rene, et al.
Publicado: (2021)

The transition from hypertension to hypertensive heart disease and heart failure: the PREFERS Hypertension study
por: Ekström, Mattias, et al.
Publicado: (2020)

Atrial Fibrillation and Heart Failure
por: Bergau, Leonard, et al.
Publicado: (2022)

Lessons learned from catheter ablation of ventricular arrhythmias in patients with a fully magnetically levitated left ventricular assist device
por: Bergau, Leonard, et al.
Publicado: (2021)

PRecision Event Monitoring for PatienTs with Heart Failure using HeartLogic (PREEMPT‐HF) study design and enrolment
por: Boehmer, John, et al.
Publicado: (2023)

Design of the GutHeart—targeting gut microbiota to treat heart failure—trial: a Phase II, randomized clinical trial
por: Mayerhofer, Cristiane C.K., et al.
Publicado: (2018)

Impact of B‐lines‐guided intensive heart failure management on outcome of discharged heart failure patients with residual B‐lines
por: Zhu, Yunlong, et al.
Publicado: (2022)

Poor humoral and T-cell response to two-dose SARS-CoV-2 messenger RNA vaccine BNT162b2 in cardiothoracic transplant recipients
por: Schramm, René, et al.
Publicado: (2021)

The genomics of heart failure: design and rationale of the HERMES consortium
por: Lumbers, R. Thomas, et al.
Publicado: (2021)

The Role of Daily Implant-Based Multiparametric Telemonitoring in Patients with a Ventricular Assist Device
por: Guckel, Denise, et al.
Publicado: (2022)

Kyoto Congestive Heart Failure (KCHF) study: rationale and design
por: Yamamoto, Erika, et al.
Publicado: (2017)

The Hearts in Rhythm Organization: A Canadian National Cardiogenetics Network
por: Davies, Brianna, et al.
Publicado: (2020)

Levosimendan displays anti-inflammatory effects and decreases MPO bioavailability in patients with severe heart failure
por: Adam, Matti, et al.
Publicado: (2015)

Natriuresis‐guided therapy in acute heart failure: rationale and design of the Pragmatic Urinary Sodium‐based treatment algoritHm in Acute Heart Failure (PUSH‐AHF) trial
por: ter Maaten, Jozine M., et al.
Publicado: (2022)

The DANish randomized, double-blind, placebo controlled trial in patients with chronic HEART failure (DANHEART): A 2 × 2 factorial trial of hydralazine-isosorbide dinitrate in patients with chronic heart failure (H-HeFT) and metformin in patients with chronic heart failure and diabetes or prediabetes (Met-HeFT)
por: Wiggers, Henrik, et al.
Publicado: (2021)

Management of heart failure with reduced ejection fraction in Europe: design of the ARIADNE registry
por: Zeymer, Uwe, et al.
Publicado: (2020)

Heart failure prevalence in the general population: SOBOTA‐HF study rationale and design
por: Lainscak, Mitja, et al.
Publicado: (2019)

Regional management of worsening heart failure: rationale and design of the CHAIN‐HF registry
por: Shakoor, Abdul, et al.
Publicado: (2023)

Third dose of the BNT162b2 vaccine in cardiothoracic transplant recipients: predictive factors for humoral response
por: Costard-Jäckle, Angelika, et al.
Publicado: (2022)

Effect of melatonin on heart failure: design for a double‐blinded randomized clinical trial
por: Sadeghi, Masoumeh, et al.
Publicado: (2020)

Rationale and design of the EPCHF trial: the early palliative care in heart failure trial (EPCHF)
por: Becher, Marc Ulrich, et al.
Publicado: (2021)

Rationale and Design of the Efficacy of a Standardized Diuretic Protocol in Acute Heart Failure Study
por: Dauw, Jeroen, et al.
Publicado: (2021)

Utilizing longitudinal data in assessing all‐cause mortality in patients hospitalized with heart failure
por: Herman, Robert, et al.
Publicado: (2022)

Rationale and design of the Clinical Evaluation of Magnetic Resonance Imaging in Coronary heart disease 2 trial (CE-MARC 2): A prospective, multicenter, randomized trial of diagnostic strategies in suspected coronary heart disease
por: Ripley, David P., et al.
Publicado: (2015)

Rationale and study design of intravenous loop diuretic administration in acute heart failure: DIUR‐AHF
por: Palazzuoli, Alberto, et al.
Publicado: (2017)

Repetitive levosimendan infusions for patients with advanced chronic heart failure in the vulnerable post‐discharge period
por: Pölzl, Gerhard, et al.
Publicado: (2018)

Rationale and design of the EMPERIAL‐Preserved and EMPERIAL‐Reduced trials of empagliflozin in patients with chronic heart failure
por: Abraham, William T., et al.
Publicado: (2019)

Study design of Heart failure Events reduction with Remote Monitoring and eHealth Support (HERMeS)
por: Yun, Sergi, et al.
Publicado: (2020)

Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial
por: Solomon, Scott D., et al.
Publicado: (2021)

Acupuncture at the auricular branch of the vagus nerve enhances heart rate variability in humans: An exploratory study
por: Boehmer, Andreas A., et al.
Publicado: (2020)

Design and rationale of the EMPA‐VISION trial: investigating the metabolic effects of empagliflozin in patients with heart failure
por: Hundertmark, Moritz J., et al.
Publicado: (2021)

Rationale and design of the AMULET study: A new Model of telemedical care in patients with heart failure
por: Krzesiński, Paweł, et al.
Publicado: (2021)

Rationale and Study Design of the Withdrawal of Spironolactone for Heart Failure with Improved Left Ventricular Ejection Fraction
por: Hyun, Junho, et al.
Publicado: (2021)

Daprodustat for anaemia in patients with heart failure and chronic kidney disease: A randomized controlled study
por: Iso, Takashi, et al.
Publicado: (2022)

Conduction system pacing and atrioventricular node ablation in heart failure: The PACE‐FIB study design
por: Rodríguez Muñoz, Daniel, et al.
Publicado: (2023)

Study design and rationale of the pAtients pResenTing with cOngenital heaRt dIseAse Register (ARTORIA‐R)
por: Sinning, Christoph, et al.
Publicado: (2021)

Autonomic regulation therapy to enhance myocardial function in heart failure patients: the ANTHEM‐HFpEF study
por: DiCarlo, Lorenzo A., et al.
Publicado: (2017)

Rationale and design of the randomized multicentre His Optimized Pacing Evaluated for Heart Failure (HOPE‐HF) trial
por: Keene, Daniel, et al.
Publicado: (2018)

Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX‐AHF‐2 study
por: Teerlink, John R., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_2u2kenbmli7350dhhthisnfens